Japan and Novo Nordisk Launch Initiative to Treat Obesity as Chronic Disease

In 2026 the Japanese Society of Obesity partnered with pharmaceutical company Novo Nordisk to promote obesity (obesity‑disease) as a chronic medical condition requiring societal and medical response. The agreement aims to improve public understanding, reduce stigma, and expand access to treatments such as the GLP‑1 drug Wegovy (semaglutide), although insurance coverage remains limited to patients meeting strict BMI and complication criteria. Advocates highlight that obesity‑related health issues—high blood pressure, dyslipidaemia, type‑2 diabetes, fatty liver, sleep‑apnoea and cardiovascular disease—drive higher medical costs, lower productivity and reduced life expectancy.

A related health overview notes that excess body fat also burdens the musculoskeletal system, increasing strain on the spine, knees and joints, and can impair organ function and breathing. The article stresses that obesity is not merely a cosmetic concern but a risk factor for multiple lifestyle‑related diseases, reinforcing the need for comprehensive prevention and treatment strategies.